{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-085826","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.636598+00:00","generated_at":"2026-05-31T13:07:23.890401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed","bullets":["Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.","Viatris collaboration revenue $14.3M, up 4% YoY; implied 35% share of YUPELRI net sales $19.1M (down 1%).","YUPELRI net sales (Viatris) $54.5M, down 1%; demand up 13% and hospital share hit all-time highs.","CYPRESS study: last patient enrollment now expected mid-2025; top-line data ~6 months later.","TRELEGY Q2 global net sales ~$1.1B (+40% YoY); up to $50M milestones achievable in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-085826","json":"https://secwatch.observer/filing/0001104659-24-085826.json","markdown":"https://secwatch.observer/filing/0001104659-24-085826.md","text":"https://secwatch.observer/filing/0001104659-24-085826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924085826/0001104659-24-085826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924085826/tm2420794d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:07:23.890401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}